Syncromune, Inc. Enters into an Exclusive Worldwide License Agreement with Eucure Biopharma Co., Ltd., to Develop and Commercialize YH002 (OX40 Antibody) and Two Undisclosed Active Ingredients as Comp
businesswire.com
news
2022-10-18 00:00:00

FORT LAUDERDALE, Fla. & BEIJING--(BUSINESS WIRE)--Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of combination intratumoral immunotherapy announced today that the Company has signed an exclusive worldwide license agreement for YH002 (OX40 antibody) and two other active ingredients with Eucure (Beijing) Biopharma Co., Ltd. ('Eucure'), a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen').

Under the terms of the agreement, Syncromune will acquire global rights of development and commercialization of the intratumoral combination therapy containing Eucure's YH002 and two other active ingredients as part of the Syncrovaxâ„¢ therapy.
